Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab with ADT and Docetaxel in mHSPC
NCT03951831Phase 2Active, not recruiting
- Start
- May 2019
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in prostate cancer (PCa). Primary endpoint: Percentage of Subjects Achieving Undetectable PSA at 6 months. Started May 2019; status: active, not recruiting.
02
Drugs
cemiplimab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03951831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03951831.